» Articles » PMID: 22706919

Usefulness of SuPAR As a Biological Marker in Patients with Systemic Inflammation or Infection: a Systematic Review

Overview
Specialty Critical Care
Date 2012 Jun 19
PMID 22706919
Citations 122
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Systemic levels of soluble urokinase-type plasminogen activator receptor (suPAR) positively correlate with the activation level of the immune system. We reviewed the usefulness of systemic levels of suPAR in the care of critically ill patients with sepsis, SIRS, and bacteremia, focusing on its diagnostic and prognostic value.

Methods: A PubMed search on suPAR was conducted, including manual cross-referencing. The list of papers was narrowed to original studies of critically ill patients. Ten papers on original studies of critically ill patients were identified that report on suPAR in sepsis, SIRS, or bacteremia.

Results: Systematic levels of suPAR have little diagnostic value in critically ill patients with sepsis, SIRS, or bacteremia. Systemic levels of suPAR, however, have superior prognostic power over other commonly used biological markers in these patients. Mortality prediction by other biological markers or severity-of-disease classification system scores improves when combining them with suPAR. Systemic levels of suPAR correlate positively with markers of organ dysfunction and severity-of-disease classification system scores. Finally, systemic levels of suPAR remain elevated for prolonged periods after admission and only tend to decline after several weeks. Notably, the type of assay used to measure suPAR as well as the age of the patients and underlying disease affect systemic levels of suPAR.

Conclusions: The diagnostic value of suPAR is low in patients with sepsis. Systemic levels of suPAR have prognostic value, and may add to prognostication of patients with sepsis or SIRS complementing severity-of-disease classification systems and other biological markers.

Citing Articles

Soluble Urokinase Plasminogen Activator Receptor: A Promising Biomarker for Mortality Prediction Among Critical ED Patients.

Wozniak P, Sieminski M, Pyrzowski J, Petrosjan R, Glogowski-Kulasza J, Leszczynski-Czeczatka J Int J Mol Sci. 2025; 26(4).

PMID: 40004075 PMC: 11855880. DOI: 10.3390/ijms26041609.


Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

Viermyr H, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas J EBioMedicine. 2024; 111():105511.

PMID: 39731852 PMC: 11743795. DOI: 10.1016/j.ebiom.2024.105511.


Soluble Urokinase-Type Plasminogen Activator Receptor and Inflammatory Biomarker Response with Prognostic Significance after Acute Neuronal Injury - a Prospective Cohort Study.

Sajanti A, Hellstrom S, Bennett C, Srinath A, Jhaveri A, Cao Y Inflammation. 2024; .

PMID: 39540961 DOI: 10.1007/s10753-024-02185-1.


Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients.

Arientova S, Matuskova K, Bartos O, Beran O, Holub M J Clin Med. 2024; 13(21).

PMID: 39518479 PMC: 11546495. DOI: 10.3390/jcm13216340.


Potential Nephroprotective Effect of uPA against Ischemia/Reperfusion-Induced Acute Kidney Injury in αMUPA Mice and HEK-293 Cells.

Alkhaleq H, Hacker I, Karram T, Hamoud S, Kabala A, Abassi Z Biomedicines. 2024; 12(10).

PMID: 39457635 PMC: 11505258. DOI: 10.3390/biomedicines12102323.


References
1.
Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen S . The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect. 2004; 10(5):409-15. DOI: 10.1111/j.1469-0691.2004.00850.x. View

2.
Sier C, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N . The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998; 58(9):1843-9. View

3.
Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A . Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011; 15(1):R63. PMC: 3221996. DOI: 10.1186/cc10037. View

4.
Ostrowski S, Ullum H, Goka B, Hoyer-Hansen G, Obeng-Adjei G, Pedersen B . Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis. 2005; 191(8):1331-41. DOI: 10.1086/428854. View

5.
Wiersinga W, Kager L, Hovius J, van der Windt G, de Vos A, Meijers J . Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol. 2010; 184(6):3079-86. DOI: 10.4049/jimmunol.0901008. View